Riley S G, Steadman R, Williams J D, Floege J, Phillips A O
Institute of Nephrology, Cardiff Royal Infirmary, Wales.
J Lab Clin Med. 1999 Sep;134(3):304-12. doi: 10.1016/s0022-2143(99)90211-1.
Diabetes is now the most common cause of kidney failure. The pathogenesis of diabetic nephropathy in both type 1 and type 2 diabetes, however, is still incompletely understood. Two mechanisms postulated to contribute to the pathogenesis of progressive diabetic nephropathy are glomerular cell proliferation and glomerular visceral epithelial cell or podocyte injury. The aim of the current study was to determine whether the aggravation of mesangial cell injury or podocyte injury in isolation would induce progressive diabetic nephropathy. Specifically, we examined whether the administration of either platelet-derived growth factor (PDGF) or basic fibroblast growth factor (bFGF) in sub-nephritogenic doses might lead to an aggravation of kidney structural changes associated with hyperglycemia, resulting in progressive kidney damage in the Goto Kakizaki (GK) rat, which is a genetic model of non-obese non-insulin-dependent diabetes mellitus (NIDDM), in which progressive kidney disease does not develop spontaneously. The results demonstrate that the administration of PDGF to hyperglycemic GK rats led to acute mesangial cell proliferation and activation as assessed by 5-bromo-2'-deoxyuridine-positive nuclei and immunostaining for alpha-smooth muscle actin. Despite acute mesangial cell activation and proliferation, PDGF treatment had no long-term effect on either kidney structure or function. Similarly, treatment of GK rats with bFGF, despite the augmentation of podocyte injury as demonstrated by de novo expression of glomerular desmin expression, did not lead to the development of progressive diabetic nephropathy. In summary, the data in the current manuscript suggest that the additive effect of hyperglycemia and superimposed isolated mesangial cell or podocyte injury does not lead to progressive diabetic nephropathy. This further emphasises the multifactorial nature of the pathogenesis of progressive diabetic nephropathy.
糖尿病现已成为肾衰竭最常见的病因。然而,1型和2型糖尿病中糖尿病肾病的发病机制仍未完全明确。目前推测导致进行性糖尿病肾病发病机制的两种机制是肾小球细胞增殖以及肾小球脏层上皮细胞或足细胞损伤。本研究的目的是确定单独的系膜细胞损伤或足细胞损伤加重是否会诱发进行性糖尿病肾病。具体而言,我们研究了给予亚肾炎剂量的血小板衍生生长因子(PDGF)或碱性成纤维细胞生长因子(bFGF)是否可能导致与高血糖相关的肾脏结构变化加重,从而在Goto Kakizaki(GK)大鼠中导致进行性肾损伤。GK大鼠是一种非肥胖非胰岛素依赖型糖尿病(NIDDM)的遗传模型,不会自发发生进行性肾病。结果表明,对高血糖GK大鼠给予PDGF后,通过5-溴-2'-脱氧尿苷阳性细胞核和α-平滑肌肌动蛋白免疫染色评估,可导致急性系膜细胞增殖和激活。尽管有急性系膜细胞激活和增殖,但PDGF治疗对肾脏结构或功能均无长期影响。同样,用bFGF治疗GK大鼠,尽管肾小球结蛋白从头表达表明足细胞损伤增加,但并未导致进行性糖尿病肾病的发生。总之,本手稿中的数据表明,高血糖与叠加的单独系膜细胞或足细胞损伤的累加效应不会导致进行性糖尿病肾病。这进一步强调了进行性糖尿病肾病发病机制的多因素性质。